aTyr Pharma Presents Research Demonstrating Effects of Novel NRP2-Targeting Antibody, ATYR2810, on Tumor Associated Macrophages at the Society for Immunotherapy of Cancer Annual Meeting
November 09, 2021 08:05 ET
|
aTyr Pharma, Inc.
Findings provide key insights into ATYR2810’s potential mechanism of action, including ability to modulate key immune cells involved in tumor progression, metastasis and therapy resistance. Data...
aTyr Pharma to Webcast Conference Call Reporting Third Quarter 2021 Financial Results
November 03, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Nov. 03, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma to Participate in Piper Sandler Investor Lung Day
October 11, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 11, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Appointment of Robert W. Ashworth, PhD, as Vice President of Regulatory Affairs
October 06, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 06, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Poster Presentation at the Society for Immunotherapy of Cancer Annual Meeting
October 01, 2021 08:01 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Oct. 01, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
Global Organ Care System for Heart Market Anticipated to Garner a Revenue of $44.02 Million at a CAGR of 19.4% during the Forecast Period, 2019-2026 COVID-19 Disaster - Exclusive Report by Research Dive
September 21, 2021 09:30 ET
|
Research Dive
New York, USA, Sept. 21, 2021 (GLOBE NEWSWIRE) -- According to a recent report by Research Dive, the global organ care system for heart market is forecasted to reach $44.02 million by the end of...
aTyr Pharma Announces Closing of $86.3 Million Public Offering Including Full Exercise of Underwriters’ Option to Purchase Additional Shares
September 20, 2021 16:07 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 20, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...
aTyr Pharma to Present at the Oppenheimer Fall Healthcare Life Sciences and MedTech Summit
September 16, 2021 16:01 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a biotherapeutics company engaged in the discovery and development of innovative medicines based on novel biological...
aTyr Pharma Announces Pricing of $75 Million Public Offering of Common Stock
September 16, 2021 08:00 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 16, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...
aTyr Pharma Announces Proposed Public Offering of Common Stock
September 15, 2021 16:01 ET
|
aTyr Pharma, Inc.
SAN DIEGO, Sept. 15, 2021 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: LIFE), a clinical stage biotherapeutics company engaged in the discovery and development of innovative medicines based on...